

## Medical Benefit Drugs

Recommendations presented February 2024

Brand	Diagnosis	AWP	Recommendation	HA Coverage Policy*
Balfaxar	Urgent reversal of anticoagulation (ex. Warfarin overdose)	\$3.78 per unit	Cover	Covered through DRG in Emergency Department or Inpatient Setting
Beyfortus	Prevention of RSV in <8 months of age	\$445 per 100mg dose	Cover	<a href="https://secure.healthadvantage-hmo.com/members/report.aspx?policyNumber=2023046">https://secure.healthadvantage-hmo.com/members/report.aspx?policyNumber=2023046</a>
Elevidys	Muscular Dystrophy with DMD gene	\$3.2 million for single dose gene therapy	Exclude	<a href="https://secure.healthadvantage-hmo.com/members/report.aspx?policyNumber=2023039">https://secure.healthadvantage-hmo.com/members/report.aspx?policyNumber=2023039</a>
Elfabrio	Fabry disease	\$48,379 per year	Cover	<a href="https://secure.healthadvantage-hmo.com/members/report.aspx?policyNumber=2023013">https://secure.healthadvantage-hmo.com/members/report.aspx?policyNumber=2023013</a>
Epkinly	B cell lymphoma	\$500,000 for 10 cycles	Cover	<a href="https://secure.healthadvantage-hmo.com/members/report.aspx?policyNumber=2023034">https://secure.healthadvantage-hmo.com/members/report.aspx?policyNumber=2023034</a>
Gohibic (EUA)	Covid-19 in mechanically ventilation or ECMO		Cover	Covered through DRG in Emergency Department or Inpatient Setting
Omisirge	Hematologic malignancies who are planned for umbilical cord		Exclude	<a href="https://secure.healthadvantage-hmo.com/members/report.aspx?policyNumber=2023026">https://secure.healthadvantage-hmo.com/members/report.aspx?policyNumber=2023026</a>
Polivy	Diffuse Large B-cell Lymphoma	\$119,000 per 6 cycles	Cover with PA	Medical Benefit PA through EBRx
Prevduo	NMBA reversal		Cover	Covered through DRG in Emergency Department or Inpatient Setting
Veopoz inj	Chaple disease	\$660,000 - \$4.3 million per year based on weight based dosing	Cover	<a href="https://secure.healthadvantage-hmo.com/members/report.aspx?policyNumber=2024002">https://secure.healthadvantage-hmo.com/members/report.aspx?policyNumber=2024002</a>
Vyvgart Hytrulo	Generalized myasthenia gravis who are AChR Ab+	\$75,000 per 28 days	Cover	<a href="https://secure.healthadvantage-hmo.com/members/report.aspx?policyNumber=2022001">https://secure.healthadvantage-hmo.com/members/report.aspx?policyNumber=2022001</a>
Zynyz	Metastatic or recurrent Merkel cell carcinoma	\$17,088 per 28 days	Cover	<a href="https://secure.healthadvantage-hmo.com/members/report.aspx?policyNumber=2023033">https://secure.healthadvantage-hmo.com/members/report.aspx?policyNumber=2023033</a>

DRG = diagnosis-related group. Categories with similar clinical diagnoses in order to better control hospital costs and determine payor reimbursement rates

Statement from Health Advantage: Our goal is to review new drugs to determine coverage policy and publish to the HA website (<https://www.healthadvantage-hmo.com/members/employer-coverage/arkansas-state-public-school>) within 6 months of the product entering the market. Health Advantage reviews are done post service, but the coverage policy criteria is available at [https://secure.healthadvantage-hmo.com/members/coverage\\_policy\\_disclaimer.aspx](https://secure.healthadvantage-hmo.com/members/coverage_policy_disclaimer.aspx) for the provider to review before administering the medication. If a medication does not have a coverage policy, medications over a certain dollar amount will pend for manual review by a Medical Director. In addition, providers may request a Formal Benefit Inquiry to determine coverage prior to administration.